INDP (Indaptus Therapeutics) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 07, 2026)


INDP Indaptus Therapeutics Inc INDP
26 GF Score
Price $2.80
! 1 Warning Sign
View Full Analysis

What is Indaptus Therapeutics 5-Year Yield-on-Cost %?

Indaptus Therapeutics INDP -5.94% 26 5-Year Yield-on-Cost % is 0.00 as of Jul. 07, 2026. GuruFocus rates INDP with a GF Score™ of 26/100. The stock has 1 warning sign investors should review. Among 152 Biotechnology companies, Indaptus Therapeutics ranks worse than 657894.08% on this metric.

Indaptus Therapeutics's yield on cost for the quarter that ended in Mar. 2026 was 0.00.


The historical rank and industry rank for Indaptus Therapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:



INDP's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.64
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Indaptus Therapeutics  (NAS:INDP) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

Indaptus Therapeutics 5-Year Yield-on-Cost % Related Terms

INDP vs EDIT, ARTV, SGMT: 5-Year Yield-on-Cost % Comparison

For the Biotechnology subindustry, Indaptus Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Indaptus Therapeutics 5-Year Yield-on-Cost % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Indaptus Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Indaptus Therapeutics's 5-Year Yield-on-Cost % falls into.


INDP
26GF Score
Indaptus Therapeutics Inc INDP
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Indaptus Therapeutics 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Indaptus Therapeutics is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Indaptus Therapeutics (INDP) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 07, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Indaptus Therapeutics and its competitors. According to the industry distribution chart, Indaptus Therapeutics ranks #999999 out of 152 companies in the Biotechnology industry.
Is Indaptus Therapeutics' 5-Year Yield-on-Cost % too high?
Indaptus Therapeutics' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Indaptus Therapeutics ranks #999999 out of 152 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Indaptus Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Indaptus Therapeutics' 5-Year Yield-on-Cost % compare to EDIT and ARTV?
According to the Biotechnology industry distribution chart, Indaptus Therapeutics ranks #999999 out of 152 companies for 5-Year Yield-on-Cost %. This places Indaptus Therapeutics in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.64. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.64, based on 152 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Indaptus Therapeutics and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Indaptus Therapeutics's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indaptus Therapeutics stock overvalued right now?
Indaptus Therapeutics (INDP) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Indaptus Therapeutics' overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Indaptus Therapeutics (INDP), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Indaptus Therapeutics Business Description

Address 3 Columbus Circle 15th Floor, New York, NY, USA, 10019
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
26GF Score

Get the complete analysis for INDP

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.80
Price